Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

Profound Medical Corp. will release its first quarter 2024 financial results on May 9, followed by a conference call to discuss the results and business developments. The company specializes in customizable, incision-free therapies for diseased tissue ablation.

TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

First Quarter 2024 Results Conference Call Details:

Date:	Thursday, May 9, 2024
Time:	4:30 p.m. ET

Live Call Registration: https://register.vevent.com/register/BI477e53fa85fe419682e13b58f27341b0

The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO^® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO^® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO^® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve^® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve^® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

FAQ

When will Profound Medical release its first quarter 2024 financial results?

Profound Medical will release its first quarter 2024 financial results after market close on Thursday, May 9, 2024.

What does Profound Medical specialize in?

Profound Medical specializes in customizable, incision-free therapies for the ablation of diseased tissue.

When is the conference call to discuss Profound Medical's first quarter 2024 financial results?

The conference call to discuss Profound Medical's first quarter 2024 financial results will take place at 4:30 p.m. ET on Thursday, May 9, 2024.

Where can I register for the live call to discuss Profound Medical's first quarter 2024 financial results?

You can register for the live call to discuss Profound Medical's first quarter 2024 financial results at https://register.vevent.com/register/BI477e53fa85fe419682e13b58f27341b0.